Arcus Biosciences (RCUS) Depreciation & Amortization (CF) (2017 - 2026)

Arcus Biosciences' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $9.0 million (down 10.0% YoY), while the FY2025 annual figure was $10.0 million, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) was $2.0 million for Q1 2026 at Arcus Biosciences, down from $3.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.0 million in Q4 2023 to a low of $1.0 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.1 million across 5 years, with a median of $2.0 million in 2022.
• Biggest YoY gain for Depreciation & Amortization (CF) was 200.0% in 2023; the steepest drop was 50.0% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2022, then soared by 200.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025, then sank by 33.33% to $2.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.0 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.